http://www.koreabiomed.com/news/articleView.html?idxno=5237
GC starts P1 trials of hemophilia treatment
GC said Thursday that it has administered the first dose of MG1113, a hemophilia treatment, to a patient participating in phase 1 clinical trial for the drug.
The company plans to evaluate the safety of MG1113 in 49 healthy adults and hemophilia patients at two hospitals — Severance Hospital and Korea University Anam Hospital.
Compared to conventional methods of injecting insufficient blood coagulation factors, MG1113 is a therapeutic agent made of antibodies that activate coagulation factors.
